Abstract: Nanoparticles for a selective, two stage delivery to tumors have been developed. The nanoparticles are initially sized so that they preferentially accumulate in the tumor tissue as a result of leakage through the defective vascular in the solid tumors. Once in the tumor tissue, the nanoparticles are cleaved hydrolytically and/or by enzymatic cleavage over time to release smaller nanoparticles carrying therapeutic, prophylactic or diagnostic agents into the necrotic interior of the tumors. This provides a simple, elegant and highly effective means of delivery drug selectively not just to tumors generally, but, more importantly, into the poorly vascularized necrotic interiors which drugs are normally unable to penetrate. The nanoparticles have a number of advantages: less toxicity due to selective accumulation only in the tumors; access into the poorly vascularized necrotic interiors of the tumor; and sustained release over a period of time within the tumor.
Type:
Application
Filed:
December 10, 2013
Publication date:
June 12, 2014
Applicants:
The Massachusetts General Hospital, Massachusetts Institute of Technology
Inventors:
Cliff R. Wong, Moungi G. Bawendi, Dai Fukumura, Rakesh K. Jain
Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3? or GSK3?) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychriatic disorders, metabolic disorders, and cancer.
Type:
Application
Filed:
October 11, 2013
Publication date:
April 17, 2014
Applicants:
The General Hospital Corporation d/b/a Massachusetts General Hospital, The Broad Institute, Inc.
Inventors:
Florence Fevrier Wagner, Jennifer Q. Pan, Sivaraman Dandapani, Andrew Germain, Edward Holson, Benito Munoz, Partha P. Nag, Michel Weiwer, Michael C. Lewis, Stephen J. Haggarty, Joshua A. Bishop
Abstract: Methods and compositions are generally provided for treating metabolic disorders, e.g., obesity. One aspect discloses methods and compositions for obtaining a biological sample from the subject, evaluating the sample for the presence or absence of a genetic indicator, wherein the genetic indicator is selected from a single nucleotide polymorphism and a level of gene expression, and performing a first metabolic procedure if the genetic indicator is present, or performing an alternative second metabolic procedure if the genetic indicator is absent. One aspect discloses methods and compositions for obtaining a sample including deoxyribonucleic acids (DNA) from the subject, evaluating the DNA for an absence or presence of one or more genetic indicators and performing a first metabolic procedure or an alternative second metabolic procedure based on the absence or presence of the genetic indicator(s). Other aspects are also disclosed.
Type:
Application
Filed:
March 14, 2013
Publication date:
March 27, 2014
Applicants:
THE GENERAL HOSPITAL CORPORATION d/b/a MASSACHUSETTS GENERAL HOSPITAL, Ethicon Endo-Surgery, Inc.
Inventors:
Lee M. Kaplan, Ida Hatoum, Jason L. Harris
Abstract: The present invention provides various biomarkers of inflammatory bowel disease, including biomarkers for Crohn's disease and biomarkers for Ulcerative colitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of inflammatory bowel disease, methods for distinguishing between inflammatory bowel diseases, methods of determining predisposition to inflammatory bowel disease, methods of monitoring progression/regression of inflammatory bowel disease, methods of assessing efficacy of compositions for treating inflammatory bowel disease, methods of screening compositions for activity in modulating biomarkers of inflammatory bowel disease, methods of treating inflammatory bowel disease, as well as other methods based on biomarkers of inflammatory bowel disease.
Type:
Grant
Filed:
April 8, 2011
Date of Patent:
March 25, 2014
Assignees:
Metabolon, Inc., The Massachusetts General Hospital
Inventors:
Danny Alexander, Jeffrey Shuster, Joshua Korzenik, Garrett Zella
Abstract: Modulation of PD-1 activity in the presence or absence of an agent as measured by a gene expression profile of at least two genes is provided. Reagents, kits, methods and uses thereof for the modulation of immune function comprise the identification of modulators of PD-1 activity.
Type:
Grant
Filed:
November 28, 2008
Date of Patent:
February 11, 2014
Assignees:
Oregon Health & Science University, Massachusetts General Hospital
Inventors:
Rafick-Pierre Sekaly, Elias Haddad, Bruce Walker, Quentin Eichbaum
Abstract: This invention is directed to ?-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The ?-1-6-glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety.
Type:
Application
Filed:
September 26, 2013
Publication date:
January 30, 2014
Applicants:
Whitehead Institute, The General Hospital Corporation d/b/a Massachusetts General Hospital, Boston University, Massachusetts Institute of Technology
Inventors:
Ifat Rubin-Bejerano, Gerald R. Fink, Claudia Abeijon, Daniel S. Kohane, Jason E. Fuller, Robert S. Langer
Abstract: The present invention generally provides methods and systems for performing in vivo flow cytometry by using blood vessels as flow chambers through which flowing cells can be monitored in a live subject in vivo without the need for withdrawing a blood sample. In some embodiments, one or more blood vessels are illuminated with radiation so as to cause a multi-photon excitation of an exogenous fluorophore that was previously introduced into the subject to label one or more cell types of interest. In some other embodiments, rather than utilizing an exogenous fluorophore, endogenous (intrinsic) cellular fluorescence can be employed for in vivo flow cytometry. The emission of fluorescence radiation from such fluorophores in response to the excitation can be detected and analyzed to obtain information regarding a cell type of interest.
Type:
Application
Filed:
September 30, 2013
Publication date:
January 30, 2014
Applicant:
The General Hospital Corporation D/B/A Massachusetts General Hospital
Inventors:
Charles P. Lin, Alicia L. Carlson, Clemens Alt, David P. Biss, Costas M. Pitsillides, Li Chunqiang
Abstract: Methods and devices are provided for activating brown adipose tissue with targeted substance delivery. Generally, the methods and devices can activate BAT to increase thermogenesis, e.g., increase heat production in the patient, which over time can lead to weight loss and/or improved metabolic function. In one embodiment, a chemical configured to stimulate nerves that activate the BAT and/or to stimulate brown adipocytes directly can be delivered to a patient, thereby increasing thermogenesis in the BAT and inducing weight loss and/or improved metabolic function through energy expenditure. The chemical can be delivered to the patient locally and/or systemically to stimulate the nerves and/or the brown adipocytes.
Type:
Application
Filed:
December 21, 2011
Publication date:
January 16, 2014
Applicants:
The General Hospital Corporation D/B/A Massachusetts General Hospital, ETHICON ENDO-SURGERY, INC.
Inventors:
Jason L. Harris, Taylor W. Aronhalt, Dwight Henninger, James W. Voegele, Lee M. Kaplan, Nicholas Stylopoulos
Abstract: The present invention relates to methods of decreasing inflammation by inhibiting polo-like kinase (PlK)
Type:
Application
Filed:
October 7, 2011
Publication date:
January 9, 2014
Applicants:
The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College, The General Hospital Corporation d/b/a Massachusetts General Hospital
Inventors:
Aviv Regev, Ido Amit, Nir Hacohen, Manuel Garber, Nicolas Chevrier
Abstract: The present invention provides polymers for use in preventing damage to the membranes of cells in fat grafts. Mixing of a triblock copolymer such as poloxymer P188 with adipocytes or adipose tissue to be transplanted into a subject is thought to stabilize the membranes of the cells leading to more successful fat transplantation in soft tissue reconstruction or augmentation. Such methods may also be used in the transplantation of adult stem cells or other cells derived from fat tissue. Other agents such as lipoic acid may also be added to the polymer/cell compositions for cell transplantation.
Type:
Application
Filed:
August 20, 2013
Publication date:
December 19, 2013
Applicant:
The General Hospital Corporation d/b/a Massachusetts General Hospital
Abstract: A novel pathway in cancer cell metabolism is identified. Targeting of any gene, protein, or enzyme that modulates activity or flux through this pathway, including, but not limited to IDH1, isocitrate dehydrogenase 2 (IDH2), aconitase 1 (ACO1), aconitase 2 (ACO2), glutaminase (GLS), glutamate dehydrogenase (GDH) and transaminase, provides effective means of inhibiting tumor growth.
Type:
Application
Filed:
July 8, 2011
Publication date:
December 12, 2013
Applicants:
The General Hospital Corporation d/b/a Massachusetts General Hospital, Massachusetts Institute Of Technology
Inventors:
Gregory Stephanopoulos, Christian M. Metallo, Joanne K. Kelleher, Othon Iliopoulos, Paulo Alexandre da Costa Gameiro Guerreiro
Abstract: The invention relates to methods and compositions for promoting cognitive function and/or treating cognitive function disorders and impairments. In particular the methods are accomplished by administering to a subject CI-994 or dinaline or a pharmaceutically acceptable salt, ester, prodrug or metabolite thereof.
Type:
Grant
Filed:
November 1, 2010
Date of Patent:
October 22, 2013
Assignees:
Massachusetts Institute of Technology, The Broad Institute, Inc., Massachusetts General Hospital
Inventors:
Li-Huei Tsai, Ji-Song Guan, Stephen J. Haggarty, Edward Holson, Florence Wagner, Johannes Graeff
Abstract: Methods and compositions are generally provided for treating metabolic disorders, e.g., obesity. One aspect discloses methods and compositions for obtaining a biological sample from the subject, evaluating the sample for the presence or absence of a genetic indicator, wherein the genetic indicator is selected from a single nucleotide polymorphism and a level of gene expression, and performing a first metabolic procedure if the genetic indicator is present, or performing an alternative second metabolic procedure if the genetic indicator is absent. One aspect discloses methods and compositions for obtaining a sample including deoxyribonucleic acids (DNA) from the subject, evaluating the DNA for an absence or presence of one or more genetic indicators and performing a first metabolic procedure or an alternative second metabolic procedure based on the absence or presence of the genetic indicator(s). Other aspects are also disclosed.
Type:
Application
Filed:
February 28, 2013
Publication date:
August 29, 2013
Applicants:
The General Hospital Corporation D/B/A Massachusetts General Hospital, ETHICON ENDO-SURGERY, INC.
Inventors:
ETHICON ENDO-SURGERY, INC., The General Hospital Corporation D/B/A Massachusetts General Hospital
Abstract: This invention relates generally to populations of microvesicles containing or otherwise associated with viral particles, methods of producing these purified populations, and methods of using these purified populations in a variety of diagnostic, therapeutic and/or prophylactic indications.
Type:
Application
Filed:
April 8, 2013
Publication date:
August 8, 2013
Applicant:
The General Hospital Corporation d/b/a Massachusetts General Hospital
Inventor:
The General Hospital Corporation d/b/a Massachusetts General Hospital
Abstract: A bundle of drawn fibers that have X-ray scintillating unagglommerated nanocrystallite particles in plastic or glass cores of down to 0.1 micron spacing and claddings of X-ray absorbing compounds in the cladding composition. Optional is a cover to the bundle that blocks light from leaving the bundle at the X-ray side while allowing X-rays to pass into the cores. To image the light exiting the fiber bundle at the sub-micron level, light expansion is preferable using either a lens system or a fiber bundle expander.
Type:
Grant
Filed:
March 5, 2008
Date of Patent:
July 2, 2013
Assignees:
Trustees of Boston University, Corporate Sponsored Research and Licensing for Massachusetts General Hospital, Partners Healthcare System, Inc.
Inventors:
Theodore F. Morse, Rajiv Gupta, Carson B. Roberts, Robert D. Chivas
Abstract: Methods and compositions are provided for treating metabolic disorders by modulating bile acid levels. Generally, the methods and compositions can modulate bile acid levels, such as serum bile acid levels, to treat a metabolic disorder. In one embodiment, a method of modulating a bile acid level includes measuring a bile acid level and delivering a composition effective to modulate the bile acid level. A method for modulating a bile acid profile includes comparing a bile acid profile to a target profile and delivering a bile acid cocktail to increase bile acid levels. In another embodiment, a pharmaceutical composition for increasing bile acid levels includes a bile acid cocktail effective to increase bile acid levels. The composition is further useful as part of an implantable system.
Type:
Application
Filed:
September 28, 2012
Publication date:
May 9, 2013
Applicants:
Ethicon Endo-Surgery, Inc., The General Hospital Corporation D/B/A Massachusetts General Hospital
Inventors:
The General Hospital Corporation D/B/A, Ethicon Endo-Surgery, Inc.
Abstract: The invention relates to methods and products for diagnosing, preventing, and treating Alzheimer's disease and abnormal production of amyloid ?.
Type:
Application
Filed:
September 14, 2012
Publication date:
January 24, 2013
Applicant:
The General Hospital Corporation d/b/a Massachusetts General Hospital
Abstract: Methods and devices are provided for knee joint replacement with anterior cruciate ligament (ACL) substitution. Generally, the methods and devices can allow a knee joint to be partially or totally replaced in conjunction with substitution of the knee joint's ACL. In one embodiment, a knee replacement prosthesis can include a medial or lateral femoral implant, a femoral intercondylar notch structure, a medial or lateral tibial insert, and an ACL-substitution member. The ACL-substitution member can be configured to engage with the femoral intercondylar notch structure during a full range of knee motion and/or during only early knee flexion.
Type:
Application
Filed:
July 12, 2012
Publication date:
January 17, 2013
Applicant:
The General Hospital Corporation D/B/A Massachusetts General Hospital
Inventors:
Orhun K. Muratoglu, Kartik Mangudi Varadarajan, Guoan Li, Harry E. Rubash, Thomas Zumbrunn
Abstract: The invention relates to compounds and composition for the treatment and prevention of cancer. The invention also covers all diseases that may be treated by selective modulation of levels of reactive oxygen species in diseased cells versus normal cells. Methods for the preparation and administration of such compositions are also disclosed.
Type:
Grant
Filed:
September 2, 2010
Date of Patent:
January 8, 2013
Assignees:
Canthera Therapeutics, The Massachusetts General Hospital Corporation
Inventors:
Michael Andrew Foley, Robert Gould, Peter Elliott, Anna Mandinova